Use of long-acting β-agonists and inhaled steroids in asthma: Meta-analysis of observational studies

Journal of Asthma

Volumn 47, Issue 4, 2010, Pages 439-446

  Hirst, Ceri ^a   Calingaert, Brian ^a   Stanford, Richard ^b   Castellsague, Jordi ^a  

^a RTI HEALTH SOLUTIONS   (United States)

^b GLAXOSMITHKLINE   (United States)

Author keywords

Asthma; Asthma exacerbations; Epidemiology; Inhaled corticosteroids; Long acting agonists; Meta analysis; Observational studies

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; LONG ACTING DRUG;

ARTICLE; ASTHMA; CLINICAL PRACTICE; CLINICAL TRIAL; COHORT ANALYSIS; DISEASE ASSOCIATION; DISEASE EXACERBATION; EMERGENCY WARD; FOLLOW UP; HOSPITALIZATION; HUMAN; META ANALYSIS; MONOTHERAPY; OBSERVATIONAL STUDY; RETROSPECTIVE STUDY; RISK ASSESSMENT; SENSITIVITY ANALYSIS; SYSTEMATIC REVIEW; UNITED STATES;

ADRENAL CORTEX HORMONES; ADRENERGIC BETA-AGONISTS; ADULT; ALBUTEROL; ANDROSTADIENES; ANTI-ASTHMATIC AGENTS; ASTHMA; BUDESONIDE; CHILD; DELAYED-ACTION PREPARATIONS; DRUG ADMINISTRATION SCHEDULE; DRUG COMBINATIONS; ETHANOLAMINES; HUMANS; METERED DOSE INHALERS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESPIRATORY FUNCTION TESTS;

EID: 77953351470     PISSN: 02770903     EISSN: 15324303     Source Type: Journal    
DOI: 10.3109/02770901003605340     Document Type: Article

References (24)

1. Global Initiative for Asthma (GINA). Global strategy for asthma management and prevention. Updated 2007. Available at: http://www. ginasthma.org. Accessed September 2008.
2. National Heart, Lung, and Blood Institute. Guidelines for the diagnosis and management of asthma (Expert Panel Report 3). July 2007. Available at: http://www.nhlbi.nih.gov/guidelines/asthma/index.htm. Accessed September 26, 2008.
3. Castle W, Fuller R, Hall J, Palmer J. Serevent nationwide surveillance study: comparison of salmeterol with salbutamol in asthmatic patients who require regular bronchodilator treatment. BMJ 1993; 306:1034-1037.
4. Nelson HS, Weiss ST, Bleecker ER, Yancey SW, Dorinsky PM, SMART study group. The Salmeterol Multicenter Asthma Research Trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. Chest 2006; 129:15-26.
5. Salpeter SR, Buckley NS, Ormiston TM, Salpeter EE.Meta-analysis: effect of long-acting beta-agonists on severe asthma exacerbations and asthmarelated deaths. Ann Intern Med 2006; 144:904-912.
6. Bateman E, Nelson H, Bousquet J, Kral K, Sutton L, Ortega H, et al. Metaanalysis: effects of adding salmeterol to inhaled corticosteroids on serious asthma-related events. Ann Intern Med 2008; 149:33-42.
7. Higgins JPT, Green S (eds.). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.0.0. The Cochrane Collaboration, February 2008. Available at: http://www.cochrane-handbook.org. Accessed August 2008.
8. Zhang O, Thomas M, Wisniewski T, Sazonov-Kocevar V, Price D. Treatment and outcomes in patients with asthma and allergic rhinitis in theUnited Kingdom. Int Arch Allergy Immunol 2007; 142:318-328.
9. Colice GL,Yu AP, Ivanova JI, Hsieh M, Birnbaum HG, Lage MJ, et al. Costs and resource use of mild persistent asthma patients initiated on controller therapy. J Asthma 2008; 45:293-299.
10. Friedman HS, Yawn BP. Resource utilization in asthma: combined fluticasone propionate/salmeterol compared with inhaled corticosteroids. Curr Med Res Opin 2007; 23:427-434.
11. ReviewManager (RevMan) [computer program].Version 5.0. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2008.
12. Symons M, Moore D. Hazard rate ratio and prospective epidemiological studies. J Clin Epidemiol 2002; 55:893-899.
13. O'Connor RD, Rosenzweig JR, Stanford RH, Gilmore AS, Ryskina KL, Legorreta AP, et al. Asthma-related exacerbations, therapy switching, and therapy discontinuation: a comparison of 3 commonly used controller regimens. Ann Allergy Asthma Immunol 2005; 95:535-540.
14. Stanford RH, Fuhlbrigge A, Riedel A, Rey GG, Stempel DA. An observational study of fixed dose combination fluticasone propionate/salmeterol or fluticasone propionate alone on asthma-related outcomes. Curr Med Res Opin 2008; 24:3141-3148.
15. i3 Innovus. Study ADA108941. Health service utilization and outcomes associated with Advair versus fluticasone propionate among asthmatics enrolled in Medicaid. Unpublished report for GlaxoSmithKline; February 18, 2008.
16. NDC Health. Study GHO101587. Readmission rates in asthma patients previously hospitalized and receiving controller medications. Unpublished report for GlaxoSmithKline; May 20, 2005.
17. Health Benchmarks, Inc. Study ADA106727. Summary report for retrospective emergency departments/hospital utilization analysis for a commercial asthma population. Unpublished report for GlaxoSmithKline; February 3, 2006.
18. MannM, Chowdhury B, Sullivan E, Nicklas R, Anthracite R, Meyer RJ. Serious asthma exacerbations in asthmatics treated with high-dose formoterol. Chest 2003; 124:70-74.
19. Jaeschke R, O'Byrne PM, Mejza F, Nair P, Lesniak W, Brozek J, et al. The safety of long-acting beta-agonists among patients with asthma using inhaled corticosteroids: systematic review and metaanalysis. Am J Respir Crit Care Med 2008; 178:1009-1016.
20. Sears MR, Ottosson A, Radner F, Suissa S. Long-acting beta-agonists: a review of formoterol safety data from asthma clinical trials. Eur Respir J 2009; 33:21-32.
21. Ni CM, Greenstone IR, Ducharme FM. Addition of inhaled long-acting beta2-agonists to inhaled steroids as first line therapy for persistent asthma in steroid-naïve adults. Cochrane Database Syst Rev 2005; (4): CD005307.
22. Greenstone IR,Ni ChroininMN, Masse V, Danish A, Magdalinos H, Zhang X, et al. Combination of inhaled long-acting beta2-agonist and inhaled steroids versus higher dose of inhaled steroids in children and adults with persistent asthma. Cochrane Database Syst Rev 2005; (4):CD005533.
23. Masoli M, Weatherall M, Holt S, Beasley R. Moderate dose inhaled corticosteroids plus salmeterol versus higher doses of inhaled corticosteroids in symptomatic asthma. Thorax 2005; 60:730-734.
24. Shrewsbury S, Pyke S, Britton M. Meta-analysis of increased dose of inhaled steroid or addition of salmeterol in symptomatic asthma (MIASMA). BMJ 2000; 320: 1368-1373.